Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Osteoporosis is a serious public health issue. The past 10 years have seen great advances in our understanding of its epidemiology, pathophysiology, and treatment, and further advances are rapidly being made. Clinical assessment will probably evolve from decisions mainly being made on the basis of bone densitometry, to use of algorithms of absolute fracture risk. Biochemical markers of bone turnover are also likely to become more widely used. Bisphosphonates will probably remain the mainstay of therapy, but improved understanding of the optimum amount of remodelling suppression and duration of therapy will be important. At the same time, other diagnostic and therapeutic approaches, including biological agents, are likely to become more widespread.

Original publication

DOI

10.1016/s0140-6736(06)68891-0

Type

Journal article

Journal

Lancet (London, England)

Publication Date

06/2006

Volume

367

Pages

2010 - 2018

Addresses

Institute of Bone and Joint Research, University of Sydney, Sydney 2065, NSW, Australia. sambrook@med.usyd.edu.au

Keywords

Humans, Osteoporosis, Calcium, Diphosphonates, Vitamin D, Risk Factors, Bone Remodeling, Aged, Middle Aged, Female, Bone Density Conservation Agents, Fractures, Bone